Tag: BioNTech

BioNTech is fundamentally realigning its business model, shifting focus from the extraordinary COVID-19 period to a clear strategic emphasis on ...

BioNTech is executing a deliberate strategy to evolve beyond its identity as a COVID-19 vaccine specialist and refocus on its ...

Investors demonstrated notable composure as news broke of a significant patent lawsuit against BioNTech. The German biotech firm, alongside its ...

BioNTech finds itself navigating a dual narrative this week, marked by a significant corporate milestone and the emergence of fresh ...

Investors in Mainz-based biotechnology firm BioNTech are navigating a complex landscape of strategic progress and fresh legal uncertainty. The company ...

Despite a challenging year for its share price, BioNTech concludes 2025 in a stronger strategic and financial position than market ...

The German biotech firm BioNTech is decisively pivoting beyond its pandemic-era identity, placing a substantial strategic bet on mRNA oncology. ...

BioNTech has completed its takeover of CureVac, a move that solidifies its commanding position within Germany's mRNA therapeutics landscape. By ...

While BioNTech stock trades near its 52-week low, a significant shift is occurring behind the scenes. Prominent institutional investors are ...

For investors in BioNTech, the company's long-stated pivot beyond its COVID-19 vaccine foundation has awaited concrete validation. This week, the ...